ArticleImmunoTargets and therapy2024

Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis.

Kaiwu Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.